BMN-680

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameBMN-680
Drug Alias NameCyp17 inhibitors (BioMarin)Cyp17 inhibitors (LEAD Therapeutics)BMN-680
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSteroid 17-alpha-hydroxylase inhibitors
TargetsSteroid 17-alpha-hydroxylase
Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLead Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiomarin Pharmaceutical IncLead Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A